Managed entry agreements: lessons from European payers

Marie-France Courriol, Brian Godman

Research output: Contribution to journalComment/debate

Abstract

At the pharmaccess leaders forum organised by nextlevel pharam in London in April 2018, Brian Godman, senior resarcher at the Stockholm Karolinska Institute, and Professor affiliated to several universities (including the university of Strathclyde, Glasgow), presented an overview of managed entry agreements (MEAs) for high-cost drugs from the niewpoint of Eurpean reimbursement agencies. He offered coference delegates insights into what pharmaceutical companies can do to conclude successful MEAs. Following the meering, he spoke to Marie-France Courriol for PPR.
LanguageEnglish
Number of pages5
JournalIMS Pharma Pricing & Reimbursement
Publication statusPublished - 1 Jul 2018

Fingerprint

Drug Costs
France
Pharmaceutical Preparations

Keywords

  • managed entry agreements
  • pharmacoeconomics
  • pharmaceutical companies
  • healthcare costs

Cite this

@article{844990de7d64458fae760795c977893e,
title = "Managed entry agreements: lessons from European payers",
abstract = "At the pharmaccess leaders forum organised by nextlevel pharam in London in April 2018, Brian Godman, senior resarcher at the Stockholm Karolinska Institute, and Professor affiliated to several universities (including the university of Strathclyde, Glasgow), presented an overview of managed entry agreements (MEAs) for high-cost drugs from the niewpoint of Eurpean reimbursement agencies. He offered coference delegates insights into what pharmaceutical companies can do to conclude successful MEAs. Following the meering, he spoke to Marie-France Courriol for PPR.",
keywords = "managed entry agreements, pharmacoeconomics, pharmaceutical companies, healthcare costs",
author = "Marie-France Courriol and Brian Godman",
year = "2018",
month = "7",
day = "1",
language = "English",
journal = "IMS Pharma Pricing & Reimbursement",
issn = "1741-5756",

}

Managed entry agreements : lessons from European payers. / Courriol, Marie-France; Godman, Brian.

In: IMS Pharma Pricing & Reimbursement, 01.07.2018.

Research output: Contribution to journalComment/debate

TY - JOUR

T1 - Managed entry agreements

T2 - IMS Pharma Pricing & Reimbursement

AU - Courriol, Marie-France

AU - Godman, Brian

PY - 2018/7/1

Y1 - 2018/7/1

N2 - At the pharmaccess leaders forum organised by nextlevel pharam in London in April 2018, Brian Godman, senior resarcher at the Stockholm Karolinska Institute, and Professor affiliated to several universities (including the university of Strathclyde, Glasgow), presented an overview of managed entry agreements (MEAs) for high-cost drugs from the niewpoint of Eurpean reimbursement agencies. He offered coference delegates insights into what pharmaceutical companies can do to conclude successful MEAs. Following the meering, he spoke to Marie-France Courriol for PPR.

AB - At the pharmaccess leaders forum organised by nextlevel pharam in London in April 2018, Brian Godman, senior resarcher at the Stockholm Karolinska Institute, and Professor affiliated to several universities (including the university of Strathclyde, Glasgow), presented an overview of managed entry agreements (MEAs) for high-cost drugs from the niewpoint of Eurpean reimbursement agencies. He offered coference delegates insights into what pharmaceutical companies can do to conclude successful MEAs. Following the meering, he spoke to Marie-France Courriol for PPR.

KW - managed entry agreements

KW - pharmacoeconomics

KW - pharmaceutical companies

KW - healthcare costs

M3 - Comment/debate

JO - IMS Pharma Pricing & Reimbursement

JF - IMS Pharma Pricing & Reimbursement

SN - 1741-5756

ER -